In this episode, Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.
Adnan Subei, DO, FAAN
Advertisement
Articles by Adnan Subei, DO, FAAN
Neurologist Adnan Subei, DO, gave clinical background on ozanimod, the supportive trials behind the drug, and its known efficacy and safety profile to date.
In this episode, Adnan Subei, DO, FAAN, discusses siponimod, a selective S1P receptor modulator approved in 2019, its clinical advantages, efficacy, and how it may be useful for patients with multiple sclerosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Results Show Symptom Gains in First Patient Dosed With UX-DA001 Cell Therapy for Parkinson Disease
2
Bringing Biomarkers to the Bedside: The Clinical Promise of Abbott’s TBI Test
3
Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc
4
De-Escalation Strategies in Multiple Sclerosis: Oral Therapies and Cladribine
5
